https://www.selleckchem.com/pr....oducts/4-hydroxynone
This study was designed to assess the tolerability, efficacy, and safety of tri-weekly irinotecan plus S-1 (IRIS) and weekly cetuximab in patients with metastatic colorectal cancer (mCRC). The main eligibility criteria were RAS wild-type mCRC with no prior chemotherapy. S-1 was given orally at a dose of 40mg/m (40-60mg) twice for 2weeks, followed by a 1-week rest. Irinotecan was given on day 1 of each cycle at a dose of 150mg/m . Cetuximab was administered on days 1 (400mg/m ), 8 (250mg/m ), and 15 (250mg/m ), and then once wee
Like
Comment
Share
